Deze is ook leuk, Onno op en top:
Operator
We will now move to Phil Nadeau from Cowen & Co. Please go ahead.
Phil Nadeau
Good morning. Thanks for taking my question. Just a follow-up to Brian's question on the TOLEDO program. Do you still expect to disclose the mechanism when 3312 starts the UC proof-of-concept trial at some point this year? Could you give us maybe a little bit more clarity on exactly when that disclosure will happen? And maybe could you remind us how 3312 versus 3970 and 4399 differ? What should we expect to see different between a pan-TOLEDO versus a TOLEDO II/III and TOLEDO III? Thanks.
Onno van de Stolpe
Thank you, Phil for the question. So I Onno promise that we will disclose the target this year, so that's a promise from us to all of the investors. So the mystery will be there for a number of months, but we will help you out of your dream there and bring you back to the reality in course of this year. That's a promise.
I can spend I think too much time to really explain the difference between all of the different profiles. I think 3970 as I said before is a compound that behaves well across tissues. So it has intrinsically the same pharmacokinetic profile than 3312, but behaves much more different after oral dosing in every tissue and that means skin joints GI tract.
3312 is a compound which has the same mechanism of action, but really only scores well in -- scores much better in GI versus other tissues. So that's why we target this to the IBD space. [indiscernible] is complete, because i.e. problems are little, but only has the anti-inflammatory activity. It does not push the pro-inflammatory cytokines. So it's really a different compound as it's only pushing down the cytokine and that currently we have only a couple of diseases in mind for that compound. But that whole explanation could take me an hour as well, which we don't have over here now. Thank you.